Infusion devices and fluid identification apparatuses and methods

Information

  • Patent Grant
  • 10646649
  • Patent Number
    10,646,649
  • Date Filed
    Tuesday, February 21, 2017
    7 years ago
  • Date Issued
    Tuesday, May 12, 2020
    4 years ago
Abstract
Medical devices and methods and apparatuses for identifying fluids in a conduit of a device are provided. An exemplary apparatus for identifying an infusate in a conduit of an infusion device includes a transmitter element for transmitting a beam of energy for interaction with the infusate. Further, the apparatus includes a receiver element for receiving a signal from the beam of energy after interaction with the infusate. Also, the apparatus includes an identifier element coupled to the receiver element for analyzing the signal to identify the infusate. The transmitter element and receiver element may form a spectroscopy device and may transmit and receive a beam of infrared light or near infrared light.
Description
TECHNICAL FIELD

Embodiments of the subject matter described herein relate generally to medical devices, and more particularly, embodiments of the subject matter relate to the identification of fluids for delivery from infusion devices.


BACKGROUND

Infusion pump devices and systems are relatively well known in the medical arts, for use in delivering or dispensing a fluid agent or infusate, such as insulin or another prescribed medication, to a patient. A typical infusion pump includes a pump drive system which typically includes a small motor and drive train components that convert rotational motor motion to a translational displacement of a plunger (or stopper) in a reservoir that delivers medication from the reservoir to the body of a user via a fluid path created between the reservoir and the body of a user. Use of infusion pump therapy has been increasing, especially for delivering insulin for diabetics.


In practice, it is desirable to facilitate preparation of infusate for delivery to a patient or user. Specifically, there is a desire to make the process of preparing the infusate quicker. Typically, a user must use a syringe to withdraw the fluid agent from a larger receptacle and fill a device reservoir. Then, the user must ensure that there are no bubbles or other foreign matter in the device reservoir before coupling the device reservoir with the infusion pump device.


Thus, there is a desire to utilize pre-filled and packaged reservoirs or cartridges with infusion pump devices. Such reservoirs may be filled and packaged in an automated system and shipped to users for convenient use. However, with pre-filled and packaged reservoirs, there is a danger that a user may couple to the infusion pump device an infusate that is different from the infusate that is intended to be delivered. For example, the pre-filled and packaged reservoir may contain a different medication than the intended infusate, or may include the correct medication but in a different concentration than intended. In either case, the delivery of an incorrect infusate may cause severe injury or death to the patient.


Accordingly, there is a need to accurately identify the infusate for delivery from infusion devices. Further, there is a need to provide an automated apparatus and method for examining a fluid in an infusion device that satisfies the various requirements that may be imposed.


BRIEF SUMMARY

Medical devices and methods and apparatuses for identifying fluids in a conduit of a device are provided. An embodiment of an apparatus for identifying an infusate in a conduit of an infusion device includes a transmitter element for transmitting a beam of energy for interaction with the infusate. Further, the apparatus includes a receiver element for receiving a signal from the beam of energy after interaction with the infusate. Also, the apparatus includes an identifier element coupled to the receiver element for analyzing the signal to identify the infusate. The transmitter element and receiver element may form a spectroscopy device and may transmit and receive a beam of infrared light or near infrared light.


In another embodiment, a medical device includes a reservoir for holding a fluid and a conduit for dispensing the fluid from the reservoir. Further, the medical device includes a spectroscopy device for examining the fluid.


Another embodiment provides a method for identifying a fluid for delivery to a body of a user. The method includes transmitting a beam of energy into contact with the fluid. Also, the method includes receiving a signal from the beam of energy after interaction with the fluid. Further, the method includes analyzing the signal to identify the fluid.


This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.





BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures, which may be illustrated for simplicity and clarity and are not necessarily drawn to scale.



FIG. 1 depicts an infusion media delivery system for use by a patient in accordance with an embodiment herein;



FIG. 2 depicts a plan view of an exemplary embodiment of a fluid infusion device suitable for use in the infusion system of FIG. 1;



FIG. 3 depicts a plan view of an exemplary embodiment of another fluid infusion device suitable for use in the infusion system of FIG. 1;



FIG. 4 depicts a plan view of an exemplary embodiment of an apparatus for examining a fluid in the fluid infusion device of FIG. 2 or 3;



FIG. 5 depicts a plan view of another exemplary embodiment of an apparatus for examining a fluid in the fluid infusion device;



FIGS. 6-10 depict schematic diagrams of the operation of the apparatus for examining a fluid of FIG. 4 or 5 in accordance with embodiments herein; and



FIG. 11 is a flow chart illustrating a method for identifying a fluid for delivery in accordance with an embodiment; and



FIG. 12 is an overlapped reflective NIR/IR spectra graph of fluid-path materials and infusates.





DETAILED DESCRIPTION

The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.


While the subject matter described herein can be implemented in any electronic device, exemplary embodiments described below are implemented in the form of medical devices, such as portable electronic medical devices. Although many different applications are possible, the following description focuses on a fluid infusion device (or infusion pump) as part of an infusion system deployment. For the sake of brevity, conventional techniques related to infusion system operation, insulin pump and/or infusion set operation, and other functional aspects of the systems (and the individual operating components of the systems) may not be described in detail here. Examples of infusion pumps may be of the type described in, but not limited to, U.S. Pat. Nos. 4,562,751; 4,685,903; 5,080,653; 5,505,709; 5,097,122; 6,485,465; 6,554,798; 6,558,320; 6,558,351; 6,641,533; 6,659,980; 6,752,787; 6,817,990; 6,932,584; and 7,621,893; each of which are herein incorporated by reference.


Embodiments of the subject matter described herein generally relate to infusion systems including a fluid infusion device having an apparatus for identifying the infusate or infusion media that is prepared for delivery to the user or patient. Embodiments provide for automated examination of the infusate to ensure that the proper infusate and the proper concentration of the infusate are coupled to the fluid infusion device. In exemplary embodiments, a transmitter and receiver pair or a combined transmitter and receiver, i.e., transceiver, is utilized to direct a beam of energy at the infusate. The beam of energy contacts and interacts with matter in the beam path and absorptive and/or reflectance spectroscopy analysis may be used to identify that material by analyzing the energy transfer between the beam of energy and the matter.


The beam of energy may be in the ultraviolet (UV), near-infrared (NIR), or infrared (IR) energy range. Radiation referred to as ultraviolet defines the wavelength of from 10 nm to 400 nm while radiation referred to as near-infrared and infrared defines the wavelength range of from about 0.8 to about 25 um. Molecules can absorb such energy without later remission by exciting certain vibrational frequencies. Molecules absorb the frequencies of polychromatic light that correspond to its molecular vibrational transitions.


The energy interacts with the fluid, i.e., the energy is absorbed, refracted and/or reflected by the fluid, and with undesired bubbles or foreign matter, such as fibrils, in the fluid. Therefore, the beam is altered by the fluid and by any undesired bubbles or foreign matter therein. The altered beam may be considered to be a signal indicative of the media through which the energy passed or from which the energy was reflected. In an exemplary embodiment, the signal is captured by the receiver and is analyzed. Analysis of the signal reveals whether the proper infusate and the proper concentration of the infusate are coupled to the fluid infusion device. For example, a spectrum of frequencies or wavelengths of the signal may be compared to known spectra of frequencies or wavelengths of medications at specific concentrations, air bubbles, or foreign materials to identify the analyzed infusate, and to identify whether air or foreign matter is present in the analyzed infusate. In an exemplary embodiment, the signal analyzed by the receiver is may be an electric or intensity reading at one or more wavelengths or may be a spectra over any selected wavelength range, such as from about 0.2 to about 16 μm.


Using UV/NIR/IR spectroscopy allows for differentiation of liquid infusate compositions from the polymeric materials used in the fluid delivery device, i.e., the polypropylene reservoir, polycarbonate cap, and polyurethane/polypropylene tubing. Thus, the liquid infusate may be spectroscopically analyzed and compared to other previously tested compositions and concentrations to identify the analyzed infusate.


The disclosure relates generally to delivery devices, systems and methods for delivering infusate or infusion media, such as a drug, to a recipient, such as a medical patient. In particular embodiments, a delivery device includes a disposable portion that secures to the recipient and that may be readily disposed of after it has been in use for a period of time. Such embodiments may be configured to provide a reliable, user-friendly mechanism to secure the delivery device to a patient for delivery of fluidic infusion media to the patient. Embodiments may be configured with feature that enhance the ease by which patients may secure the delivery device to the patient's skin and further features that enhance the ease by which patients may fill, re-fill or replace spent infusion media.


While embodiments are described herein with reference to an insulin delivery example for treating diabetes, other embodiments may be employed for delivering other infusion media to a patient for other purposes. For example, further embodiments may be employed for delivering other types of drugs to treat diseases or medical conditions other than diabetes, including, but not limited to drugs for treating pain or certain types of cancers, pulmonary disorders or HIV. Thus, the infusate may be insulin, HIV drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like. Further embodiments may be employed for delivering media other than drugs, including, but not limited to, nutritional media including nutritional supplements, dyes or other tracing media, saline or other hydration media, or the like.


A generalized representation of an infusion media delivery system 10 is shown in FIG. 1, wherein the system includes an infusion or delivery device 12 configured according to embodiments described herein. In the illustrated embodiment of FIG. 1, the delivery device 12 is designed as a portable medical device suitable for infusing an infusate, i.e., a fluid, a liquid, a gel, or other agent, into the body of a user.


The infusion media delivery system 10 may also include other components coupled for communication with the delivery device 12, including, but not limited to, a sensing arrangement 14 such as a sensor or monitor, a command control device (CCD) 16, and a computer 18. Each of the CCD 16, the computer 18 and the delivery device 12 may include receiver or transceiver electronics that allow communication with other components of the system. The delivery device 12 may include electronics and software for analyzing sensor data and for delivering infusion media according to sensed data and/or pre-programmed delivery routines. Some of the processing, delivery routine storage and control functions may be carried out by the CCD 16 and/or the computer 18, to allow the delivery device 12 to be made with more simplified electronics. However, in other embodiments, the infusion media delivery system 10 may comprise delivery device 12 without any one or more of the other components of the infusion media delivery system 10 shown in FIG. 1. The elements of the infusion media delivery system 10 may be similar to those described in U.S. Pat. No. 8,674,288, the subject matter of which is hereby incorporated by reference in its entirety.


In the generalized system diagram of FIG. 1, the delivery device 12 and sensor or monitor 14 are secured to a patient-user. The locations at which those components are secured to the patient-user in FIG. 1 are provided only as a representative, non-limiting example. The delivery device 12 and sensor or monitor 14 may be secured at other locations on the patient, and such locations may depend upon the type of treatment to be administered by the infusion media delivery system 10. As described in further detail below, the delivery device 12 contains a reservoir of infusate or infusion media and delivers the infusate into the patient's body in a controlled manner.


The sensing arrangement 14 generally represents the components of the fluid delivery or infusion media delivery system 10 configured to sense, detect, measure or otherwise quantify a condition of the user, and may include a sensor, a monitor, or the like, for providing data indicative of the condition that is sensed, detected, measured or otherwise monitored by the sensing arrangement. In this regard, the sensing arrangement 14 may include electronics and enzymes reactive to a biological or physiological condition of the user, such as a blood glucose level, or the like, and provide data indicative of the blood glucose level to the infusion device 12, the CCD 16 and/or the computer 18. For example, the infusion device 12, the CCD 16 and/or the computer 18 may include a display for presenting information or data to the user based on the sensor data received from the sensing arrangement 14, such as, for example, a current glucose level of the user, a graph or chart of the user's glucose level versus time, device status indicators, alert messages, or the like. In other embodiments, the infusion device 12, the CCD 16 and/or the computer 18 may include electronics and software that are configured to analyze sensor data and operate the infusion device 12 to deliver fluid to the body of the user based on the sensor data and/or preprogrammed delivery routines. Thus, in exemplary embodiments, one or more of the infusion device 12, the sensing arrangement 14, the CCD 16, and/or the computer 18 includes a transmitter, a receiver, and/or other transceiver electronics that allow for communication with other components of the infusion media delivery system 10, so that the sensing arrangement 14 may transmit sensor data or monitor data to one or more of the infusion device 12, the CCD 16 and/or the computer 18.


Still referring to FIG. 1, in various embodiments, the sensing arrangement 14 may be secured to the body of the user or embedded in the body of the user at a location that is remote from the location at which the infusion device 12 is secured to the body of the user. In various other embodiments, the sensing arrangement 14 may be incorporated within the infusion device 12. In other embodiments, the sensing arrangement 14 may be separate and apart from the infusion device 12, and may be, for example, part of the CCD 16. In such embodiments, the sensing arrangement 14 may be configured to receive a biological sample, analyte, or the like, to measure a condition of the user.


In various embodiments, the CCD 16 and/or the computer 18 may include electronics and other components configured to perform processing, delivery routine storage, and to control the infusion device 12 in a manner that is influenced by sensor data measured by and/or received from the sensing arrangement 14. By including control functions in the CCD 16 and/or the computer 18, the infusion device 12 may be made with more simplified electronics. However, in other embodiments, the infusion device 12 may include all control functions, and may operate without the CCD 16 and/or the computer 18. In various embodiments, the CCD 16 may be a portable electronic device. In addition, in various embodiments, the infusion device 12 and/or the sensing arrangement 14 may be configured to transmit data to the CCD 16 and/or the computer 18 for display or processing of the data by the CCD 16 and/or the computer 18.


In some embodiments, the CCD 16 and/or the computer 18 may provide information to the user that facilitates the user's subsequent use of the infusion device 12. For example, the CCD 16 may provide information to the user to allow the user to determine the rate or dose of medication to be administered into the user's body. In other embodiments, the CCD 16 may provide information to the infusion device 12 to autonomously control the rate or dose of medication administered into the body of the user. In some embodiments, the sensing arrangement 14 may be integrated into the CCD 16. Such embodiments may allow the user to monitor a condition by providing, for example, a sample of his or her blood to the sensing arrangement 14 to assess his or her condition. In some embodiments, the sensing arrangement 14 and the CCD 16 may be used for determining glucose levels in the blood and/or body fluids of the user without the use of, or necessity of, a wire or cable connection between the infusion device 12 and the sensing arrangement 14 and/or the CCD 16.


In one or more exemplary embodiments, the sensing arrangement 14 and/or the infusion device 12 are cooperatively configured to utilize a closed-loop system for delivering fluid to the user. Examples of sensing devices and/or infusion pumps utilizing closed-loop systems may be found at, but are not limited to, the following U.S. Pat. Nos. 6,088,608, 6,119,028, 6,589,229, 6,740,072, 6,827,702, 7,323,142, and 7,402,153, all of which are incorporated herein by reference in their entirety. In such embodiments, the sensing arrangement 14 is configured to sense or measure a condition of the user, such as, blood glucose level or the like. The infusion device 12 is configured to deliver fluid in response to the condition sensed by the sensing arrangement 14. In turn, the sensing arrangement 14 continues to sense or otherwise quantify a current condition of the user, thereby allowing the infusion device 12 to deliver fluid continuously in response to the condition currently (or most recently) sensed by the sensing arrangement 14 indefinitely. In some embodiments, the sensing arrangement 14 and/or the infusion device 12 may be configured to utilize the closed-loop system only for a portion of the day, for example only when the user is asleep or awake.


An example of a patch-like delivery device 12 according to an embodiment is shown in FIG. 2. The delivery device 12 in FIG. 2 includes a disposable portion 20 and a durable portion 22. The disposable portion 20 may include structural elements that ordinarily contact the patient's skin or infusion media, during operation of the delivery device 12. On the other hand, the durable portion 22 may have elements (including electronics, motor components, linkage components, and the like) that do not ordinarily contact the patient or infusion media during operation of the delivery device 12. Thus, elements in the durable portion 22 of the delivery device 12 are typically not contaminated from contact with the patient or infusion media during normal operation of the delivery device 12.


In the illustrated embodiment, the disposable portion of the delivery device 12 comprises a disposable base portion 20 that supports a reservoir 24. The durable portion 22 may comprise a housing that secures onto the base portion 20 and covers the reservoir 24. The durable portion 22 may house a suitable drive device, such as an electrically operated motor (not shown in FIG. 2), and drive linkage components (not shown in FIG. 2) for driving fluid out of the reservoir 24. The durable portion 22 also may house suitable control electronics (not shown in FIG. 2) for controlling the operation of the drive device to drive fluid from the reservoir 24 in a controlled manner. Further embodiments may include communication electronics (not shown in FIG. 2) within the durable portion 22, for communicating with the sensor or monitor 14, the CCD 16, the computer 18 and/or other components of the infusion media delivery system 10.


The disposable base portion 20 has a bottom surface (facing downward and into the page in FIG. 2) that is configured to secure to a patient's skin at a desired location on the patient. A suitable adhesive may be employed at the interface between the bottom surface of the base portion 20 and the patient's skin, to adhere the base portion 20 to the patient's skin. The adhesive may be provided on the bottom surface of the base portion 20, with a removable cover layer covering the adhesive material. In this manner, a patient-user may peel off the cover layer to expose the adhesive material and then place the adhesive side of the base portion 20 against the patient's skin.


The base portion 20 may include a suitable opening or port 23 for connecting a hollow tube 25 to the reservoir 24, to convey infusion media from the reservoir 24. One end of the tube 25 may have a suitable connector 26, such as, but not limited to a Luer connector or a threaded cap connector having a hollow needle for coupling (in fluid-flow communication) to a corresponding connector 27 on the reservoir 24. Alternatively or in addition, the reservoir 24 may include a septum as part of the connector 27, for receiving an end of a hollow needle. The opening or port on the base portion 20 may be provided with corresponding connector structure, such as, but not limited to a Luer connector receptacle or a threaded receptacle shaped to receive a threaded cap connector. Other embodiments may employ other suitable connectors or connection arrangements for connecting one end of the tube 25 in fluid-flow communication with the reservoir 24.


The other end of the tube 25 may connected to a hollow needle 21 for piercing the patient's skin and conveying infusion media into the patient. The hollow needle 21 may be secured to the patient's skin, for example, by manual application or with the assistance of an insertion tool, such as, but not limited to the insertion tool described in U.S. Patent Application Publication No. 2002/0022855, titled “Insertion Device For An Insertion Set And Method Of Using The Same.” In other embodiments, as described below, a hollow needle and insertion mechanism may be included within the delivery device 12, so as to avoid the need for a port 23, tube 25 and connector 26.


The durable portion 22 of the delivery device 12 includes a housing shell configured to mate with and secure to the disposable base portion 20. The durable portion 22 and base portion 20 may be provided with correspondingly shaped grooves, notches, tabs or other suitable features that allow the two parts to easily snap together, by manually pressing the two portions together in a manner well known in the mechanical arts. In a similar manner, the durable portion 22 and base portion 20 may be separated from each other by manually applying sufficient force to unsnap the two parts from each other. In further embodiments, a suitable seal, such as an o-ring seal, may be placed along the peripheral edge of the base portion 20 and/or the durable portion 22, so as to provide a seal against water between the base portion 20 and the durable portion 22.


The durable portion 22 and base portion 20 may be made of suitably rigid materials that maintain their shape, yet provide sufficient flexibility and resilience to effectively snap together and apart, as described above. The base portion 20 material may be selected for suitable compatibility with the patient's skin. For example, the base portion 20 and the durable portion 22 of the delivery device 12 may be made of any suitable plastic, metal, composite material or the like. The base portion 20 may be made of the same type of material or a different material relative to the durable portion 22. The base portion and durable portions may be manufactured by injection molding or other molding processes, machining processes or combinations thereof.


For example, the base portion 20 may be made of a relatively flexible material, such as a flexible silicon, plastic, rubber, synthetic rubber or the like. By forming the base portion of a material capable of flexing with the patient's skin, a greater level of patient comfort may be achieved when the base portion is secured to the patient's skin. Also, a flexible base portion 20 can result in an increase in the site options on the patient's body at which the base portion 20 may be secured.


In the embodiment illustrated in FIG. 2, the durable portion 22 of the delivery device 12 is connected to sensor 14, through a sensor lead 29. Sensor 14 may comprise any suitable biological or environmental sensing device, depending upon the nature of the treatment to be administered by the delivery device 12. For example, in the context of delivering insulin to a diabetes patient, the sensor 14 may comprise a blood glucose sensor.


The sensor 14 may be an external sensor that secures to the patient's skin or, in other embodiments, may be an implantable sensor that is located in an implant site within the patient. In the illustrated example of FIG. 2, the sensor 14 is an external sensor having a disposable needle pad 14′ that includes a needle for piercing the patient's skin and enzymes and/or electronics reactive to a biological condition, such as blood glucose level, of the patient. The disposable needle pad 14′ may electrically contact electrical conductors in the lead 29, to convey electrical signals from the sensor 14 to suitable sensor electronics located within the durable portion 22 of the delivery device 12. The lead 29 may have any suitable length. In this manner, the delivery device 12 may be provided with sensor data from a sensor secured to the patient, at a site remote from the location at which the delivery device 12 is secured to the patient.


While the embodiment shown in FIG. 2 includes a sensor 14 connected by a lead 29 for providing sensor data to sensor electronics located within the durable portion 22 of the delivery device 12, other embodiments may employ a sensor 14 located within the delivery device 12. Yet other embodiments may employ a sensor 14 having a transmitter for communicating sensor data by a wireless communication link with to receiver electronics located within the durable portion 22 of the delivery device 12. The wireless connection between the sensor 14 and the receiver electronics in the durable portion 22 of the delivery device 12 may comprise a radio frequency RF connection, an optical connection, or another wireless suitable communication link. Further embodiments need not employ a sensor and, instead, provide infusion media delivery functions without the use of sensor data.


As described above, by separating disposable elements of the delivery device 12 from durable elements, the disposable elements may be arranged on the disposable base portion 20, while durable elements may be arranged within a separable durable portion 22. In this regard, after one (or a prescribed number) of uses of the delivery device 12, the disposable base portion 20 may be separated from the durable portion 22, so that the disposable base portion 20 may be disposed of in a proper manner. The durable portion 22 may, then, be mated with a new (un-used) disposable base portion 20 for further delivery operation with a patient.


The reservoir 24 may be supported by the disposable base portion 20 in any suitable manner. The reservoir 24 may be provided as a cartridge or generally cylindrical canister for containing fluidic infusion media. For example, the base portion 20 may be provided with projections or struts, or a trough feature for holding a cartridge-type reservoir in a manner that allows a user to readily remove the reservoir from the base portion and re-install a new or refilled reservoir, when replacement or re-filling is needed, as described with respect to further embodiments below. Alternatively, or in addition, the reservoir 24 may be secured to the base portion 20 by a suitable adhesive or other coupling structure. The reservoir 24 has a port and may be supported by the base portion 20 in a position at which a connector 26 may engage or otherwise come into fluid flow communication with the reservoir port, when the connector 26 is connected to the port 23 on the base portion 20.


The durable portion 22 of the delivery device 12 may include a motor or other force-applying mechanism, for applying a force to the infusion media within the reservoir 24 to force fluidic infusion media out of the reservoir 24 and into the needle, for delivery to the patient. For example, an electrically driven motor may be mounted within the durable portion 22 with appropriate linkage for causing the motor to operably engage a piston of the reservoir and drive the reservoir piston in a direction to cause the fluidic pressure within the reservoir 24 to increase and thereby force fluidic infusion media out of the reservoir port, into the tube 25 and needle. The motor may be arranged within the durable portion 22 and the reservoir may be correspondingly arranged on the disposable portion 20, such that the operable engagement of the motor with the reservoir piston (e.g., through appropriate linkage) occurs automatically upon the patient-user snap fitting the durable portion 22 onto the disposable portion 20 of the delivery device 12.


While FIG. 2 illustrates an embodiment of a patch-like delivery device 12 for use in the fluid delivery system 10, FIG. 3 illustrates an exemplary embodiment of a fluid infusion delivery device 12 coupled with an infusion set 104 with a fluid conduit assembly for use in the fluid delivery system 10 of FIG. 1. The fluid infusion delivery device 12 accommodates a fluid reservoir (hidden from view in FIG. 3) for the infusate to be delivered to the user.


The illustrated embodiment of the infusion set 104 includes, without limitation: a length of tubing 110; an infusion unit 112 coupled to the distal end of the tubing 110; and a connector 114 coupled to the proximal end of the tubing 110. The fluid infusion delivery device 12 is designed to be carried or worn by the patient, and the infusion set 104 terminates at the infusion unit 112 such that the fluid infusion delivery device 12 can deliver fluid to the body of the patient via the tubing 110. The infusion unit 112 includes a cannula (hidden from view in FIG. 3) that is coupled to the distal end of the tubing 110. The cannula is inserted into the skin and is held in place during use of the fluid infusion delivery device 12.


The infusion set 104 defines a fluid flow path that couples a fluid reservoir to the infusion unit 112. The connector 114 mates with and couples to a section of the fluid reservoir (not shown), which in turn is coupled to a housing 120 of the fluid infusion delivery device 12. The connector 114 establishes the fluid path from the fluid reservoir to the tubing 110. Actuation of the fluid infusion delivery device 12 causes the medication fluid to be expelled from the fluid reservoir, through the infusion set 104, and into the body of the patient via the infusion unit 112 and cannula at the distal end of the tubing 110. Accordingly, when the connector 114 is installed as depicted in FIG. 3, the tubing 110 extends from the fluid infusion delivery device 12 to the infusion unit 112, which in turn provides a fluid pathway to the body of the patient.


The fluid infusion delivery device 12 includes a radio frequency (RF) antenna to support wireless data communication with other devices, systems, and/or components. The RF antenna can be located inside the housing 120 or it can be integrally formed with the housing 120. Accordingly, the RF antenna is hidden from view in FIG. 3.


As may be understood from FIGS. 1-3, each embodiment of the fluid delivery device 12 includes a reservoir for holding an infusate and a fluid path for delivering the infusate from the reservoir to the patient. Other embodiments of fluid delivery devices 12 are contemplated herein for use with the infusate identifying apparatus and method. The reservoir and fluid path in such fluid delivery devices 12 are considered to be portions of a conduit in which the infusate is contained and flows. FIGS. 4 and 5 illustrate embodiments in which a portion of the fluid delivery device 12 is provided with an apparatus for identifying the infusate and any foreign matter within the infusate while located in the conduit.


In FIG. 4, an identifying apparatus 200 is located on or otherwise coupled to the connector 114 of the fluid delivery device of FIG. 3. It is contemplated that the identifying apparatus 200 of FIG. 4 may be utilized with other types of fluid delivery devices. As shown, the connector 114 defines a fluid path 210 in which the infusate may be contained and through which the infusate may flow. Fluid communication may be established between the fluid path 210 and the reservoir (not shown) through a coupling or fitting 215.


The fluid path 210 may be defined and bounded by a wall 220. Wall 220 may be transparent, translucent, or otherwise transmit the interrogating beam of energy (described below). An exemplary wall 220 is substantially transparent. For example, wall 220 may be formed from a transparent material such as clear polycarbonate, polypropylene, polyurethane/polypropylene, or other clear polymeric material. Alternatively or additionally, the wall 220 of the fluid path 210 may be formed with a window 225 that is transparent, translucent, or otherwise transmit the interrogating beam of energy. An exemplary transparent window 225 may be formed from clear polycarbonate, polypropylene, polyurethane/polypropylene, or other clear polymeric material.


As shown in FIG. 4, the identifying apparatus 200 includes a transmitter element 230. Transmitter element 230 may be a standalone transmitter or part of a transceiver device that transmits and receives. An exemplary transmitter element 230 is arranged to transmit a beam of energy into the fluid path 210, either through wall 220 or through a window 225 in wall 220, for interaction with an infusate contained within the fluid path 210. An exemplary transmitter element 230 is an infrared (IR), near infrared (NIR) or ultraviolet (UV) emitter and is arranged to transmit a beam of IR, NIR or UV energy into the fluid path 210. In an exemplary embodiment, the transmitter element transmits the beam of energy into the fluid orthogonally to the direction of fluid flow.


Further, the exemplary identifying apparatus 200 includes a receiver element 235. Receiver element 235 may be a standalone receiver or part of a transceiver device that transmits and receives. An exemplary receiver element 235 is arranged to receive a beam of energy from the fluid path 210, either through wall 220 or through a window 225 in wall 220. An exemplary transmitter element 230 is an infrared (IR), near infrared (NIR) or ultraviolet (UV) receiver and is arranged to receive a beam of IR, NIR or UV energy from the fluid path 210.


As shown in FIG. 4, the receiver element 235 may be located on an opposite side of the fluid path 210 from the transmitter element 230 to receive a signal, in the form of an altered beam of energy, that passes through the fluid path 210. Alternatively, a receiver element 235′ may be located on the same side of the fluid path 210 as the transmitter element 230 to receive a signal, in the form of an altered beam of energy, that is reflected from the fluid path 210. The transmitter element 230 and receiver element 235 may be in wired or wireless electronic connection with receiver electronics that may communicate with sensing arrangement 14, CCD 16 or computer 18 of FIG. 1. The receiver electronics, sensing arrangement 14, CCD 16 or computer 18 may include an identifier element for analyzing an electronic representation of the signal of the altered beam of energy received by a receiver element 235.


The signal received by the receiver element 235 differs from the initial beam of energy transmitted by the transmitter element 230. Specifically, absorption and/or reflectance of radiation, as a function of frequency or wavelength, results from interaction of the beam of energy with the infusate and any foreign matter in the fluid path 210 (as well as the window 225). Therefore, the resulting beam or signal exiting the fluid path 210 includes a lower radiation intensity, particularly at specific frequencies or wavelengths. The radiation spectrum of the signal exiting the fluid path 210 provide a identifiable signature or fingerprint associated with the matter on which the beam was directed and may be used in analysis as described below. The electronic representation of the signal that is analyzed by the identifier element may include electric or intensity readings at one or more wavelengths or a spectra over an selected range of wavelengths, such as from 0.2 to 16 μm.



FIG. 5 illustrates an embodiment in which the identifying apparatus 200 is provided for use with a fluid delivery device 12 as illustrated in FIG. 2. In FIG. 5, the reservoir 24 is shown as being mounted in the durable portion 22 of the delivery device. As shown, the reservoir 24 includes a connector 27 for mating connection with the hollow tube as discussed above in relation to FIG. 2. As used herein, any of the components containing or delivering a flow of an infusate are considered a conduit.


In FIG. 5, a wall 220 bounds and defines the reservoir 24. The wall 220 may be transparent, translucent, or otherwise transmit the interrogating beam of energy as described above in relation to FIG. 4. In FIG. 5, the wall 220 is illustrated as includes a window 225 that is transparent to the intended type of interrogating beam energy and response signal energy.


Further, the fluid delivery device in FIG. 5 includes a transceiver 240 that includes both a transmitter element and a receiver element. The transceiver 240 is aligned with the window 225 so that the transceiver 240 may transmit a beam of energy through the window 225 and into contact with an infusate located in the reservoir 24, and may receive a reflected beam of energy from the infusate and through the window 225.


As further shown, the transceiver 240 is mounted to a printed circuit board (PCB) 245 that may be part of receiver electronics located within the durable portion 22. The PCB 245 may be in communication with sensing arrangement 14, CCD 16 or computer 18 of FIG. 1 through the receiver electronics. The PCB 245 may serve as an identifier element for analyzing a signal received by a receiver element of the transceiver 240. Alternatively, the sensing arrangement 14, CCD 16 or computer 18 may include an identifier element for analyzing a signal received by a receiver element of the transceiver 240. In either case, the identifier element may analyze an electronic representation of the signal that may include electric or intensity readings at one or more wavelengths or a spectra over an selected range of wavelengths, such as from 0.2 to 16 μm.


While FIG. 4 illustrates an embodiment in which the identifying apparatus 200 includes a transmitter element 230 and receiver element 235 mounted to the connector 114 and FIG. 5 illustrates an embodiment in which the identifying apparatus 200 includes a transceiver 240 that is mounted to a durable portion 22, other embodiments are contemplated. For example, the transmitter element 230 and receiver element 235 may be physically decoupled from the conduit where analysis is to be performed. Also, the elements 230 and 235 may be mounted to the wall 220 of the conduit where analysis is to be performed. Further, elements 230 and 235 may be located within the conduit where analysis is to be performed. Also, elements 230 and 235 could be formed as parts of other components within the fluid delivery device. As contemplated herein, the identifying apparatus 200, including elements 230 and 235, may be located in any suitable location along the fluid path of a fluid delivery device 12. Further, a fluid delivery device 12 may be provided with more than one identifying apparatus 200, each including elements 230 and 235. In an exemplary embodiment, each of the identifying apparatuses 200 transmits a beam of energy into the fluid orthogonally to the direction of fluid flow or to the wall of the vessel through which the fluid flows.



FIGS. 6-10 illustrate the use of transmitter elements 230 and receiver elements 235 of an identifying apparatus 100 to identify the composition and concentration of a fluid or infusate 280 within a conduit 260, such as a reservoir, hollow tube, or other fluid path, that is bound by a wall 220. In the embodiments of FIGS. 6-10, the wall 220 is transparent and does not include a separate distinct window as illustrated in the embodiments of FIGS. 4-5. In FIGS. 6-10, a beam of energy 300, such as IR, NIR, or UV energy, is transmitted into the conduit 260 through the wall 220 from a first side 301 of the conduit 260. The beam of energy 300 interacts with the infusate 280 and any foreign matter. For example, different portions or wavelength ranges of the beam of energy 300 may be absorbed, refracted or reflected. In certain embodiments, a resulting beam of energy passes through the conduit 260 and to the opposite second side 302 of the conduit 260. In other embodiments, a resulting beam of energy reflects from the conduit 260 back to the first side 301 of the conduit 260.


Referring now to FIG. 6, an embodiment is illustrated in which a transmitter element 230 is located on the first side 301 of the conduit 260 and the receiver element 235 is located on the second side 302 of the conduit 260. The transmitter element 230 transmits a beam of energy through the wall 220 and into the conduit 260 into contact with the infusate 280. As described above, the beam of energy 300 interacts with the infusate 280 and a resulting beam of energy 310 passes through the conduit 260 and exits to the second side 302 of the conduit 260. As shown, the resulting beam of energy 310 is received by receiver element 235 as a signal. The signal can be analyzed as described below in relation to FIG. 11 to determine the composition and concentration of the infusate 280 and whether foreign matter is present in the infusate 280.



FIG. 7 illustrates an embodiment in which both the transmitter element 230 and the receiver element 235 are located on the first side 301 of the conduit 260. In FIG. 7, the transmitter element 230 transmits the beam of energy 300 through the wall 220 and into the conduit 260 into contact with the infusate 280. The beam of energy 300 interacts with the infusate 280 and a resulting beam of energy 310 is reflected back out of the conduit and to the first side 301 of the conduit 260. As shown, the resulting beam of energy 310 is received by receiver element 235 as a signal and can be analyzed as described below. It is contemplated that an embodiment may use both an opposite side receiver element 235 of FIG. 6 and a same side receiver element 235 of FIG. 7 for receiving the resulting beam of energy 310.



FIG. 8 illustrates a similar structural arrangement as FIG. 7. However, in FIG. 8, it is contemplated that the beam of energy 300 transmitted by transmitter element 230 is reflected by the infusate 280 at the interface 290 of the infusate 280 and the wall 220. As shown, the reflected beam of energy 310 passes back through the wall 220 and is received by the receiver element 235 as a signal for analysis.



FIGS. 9 and 10 illustrate a transceiver 240 including a transmitter element 230 and receiver element 235. Necessarily, the transmitter element 230 and receiver element 235 are each located on the first side 310 of the conduit 260. In FIG. 9, the transmitter element 230 transmits the beam of energy 300 through the wall 220 and into the conduit 260 into contact with the infusate 280. The beam of energy 300 interacts with the infusate 280 and a resulting beam of energy 310 is reflected back out of the conduit and to the first side 301 of the conduit 260. As shown, the resulting beam of energy 310 is received by receiver element 235 as a signal for analysis.



FIG. 10 illustrates a similar structural arrangement as FIG. 9. In FIG. 10, it is contemplated that the beam of energy 300 transmitted by transmitter element 230 is reflected by the infusate 280 at the interface 290 of the infusate 280 and the wall 220. As shown, the reflected beam of energy 310 passes back through the wall 220 and is received by the receiver element 235 as a signal for analysis.


It is contemplated that an embodiment may use one or more arrangements of transmitter elements 230, receiver elements 235, and/or transceivers 240 of FIGS. 6-10, such as with both same side and opposite side receiver elements 235 for receiving the resulting beam of energy 310.


After the signal of the resulting beam of energy 310 is received by the receiver element 235 in FIGS. 6-10, analysis is performed to identify the composition of the infusate 280, the concentration of the infusate, and/or the presence of foreign matter in the infusate 280. For example, spectroscopic analysis may be performed and compared to a library of known spectral signatures.



FIG. 11 illustrates an exemplary method 400 for identifying a fluid for delivery to a body of a user. As shown, an infusate reservoir or other container with a conduit holding an infusate is coupled to a fluid delivery device at step 402. Upon coupling, the identification process may be initiated to confirm that the correct infusate is loaded in the fluid delivery device. Alternatively, the identification process may be initiated when fluid is forced out of the reservoir and through a testing location elsewhere in the fluid conduit. For example, at step 404, a beam of energy is transmitted from the transmitter element into the conduit holding the infusate. The beam of energy interacts with the infusate and exits the conduit as a resulting beam of energy. As used herein, a beam of energy reflected at the interface of the conduit and wall bounding the conduit is considered to have passed through the wall and exits the conduit upon reflection with the interface. At step 406, the resulting beam of energy is received by the receiver element.


At step 408, the signal of the resulting beam of energy is communicated from the receiver element to an identifier element. For example, the signal may be wirelessly communicated from the receiver element to the identifier element. The identifier element may be contained within a PCB, sensing arrangement, CCD or computer. The signal is or includes spectroscopic data that may be represented by a spectrum that may be plotted as a graph of energy absorbance (or transmittance) on the vertical axis vs. frequency or wavelength on the horizontal axis.


The identifier element includes or is coupled to a memory storage or library of spectra of known, i.e., previously tested compositions and concentrations. The memory stores data associated with selected fluids for comparison with detected characteristics of the signal. At step 410, the spectrum of the signal is compared to the spectra of known compositions and concentrations. For example, the identifier element may use the stored data to identify the infusate based on the received signal. As is known in absorptive spectroscopic analysis, different compositions and different concentrations of those compositions exhibit unique spectra or signature spectra. For example, differing values of intensity of radiation at specific wavelengths or frequencies or over specific ranges of wavelengths or frequencies may indicate that the beam of energy passed through a specific concentration of a specific composition. As an example, a reflective NIR/IR spectra graph of fluid-path materials and infusates (insulin formulations) is presented in FIG. 12, in which the spectral different regions may be used for infusate/bubble tracking. In the exemplary embodiment of FIG. 12, reflective NIR/IR spectra of fluid-path materials and infusates indicate that there are two NIR regions (around 1.7 μm or around 3 μm) that may be used for infusate tracking inside the polymeric component (reservoir, p-cap, or tubing). Spectroscopic signals at various wavelengths may be orthogonally used for better identification accuracy.


At step 412, the method queries whether, based on the signal spectrum comparison, the proper or expected infusate is loaded in the fluid delivery device. If not, the PCB, sensing arrangement, CCD or computer may automatically alert the user and/or disable infusion of the infusate from the fluid delivery device at step 414. On the other hand, if the correct infusate is loaded, the PCB, sensing arrangement, CCD or computer may confirm that the correct infusate is loaded and allow the fluid delivery device to proceed with an infusion process at step 416.


While the subject matter is described above primarily in the context of a pre-loaded reservoir containing insulin reservoir for regulating a glucose level of a user, the subject matter described herein is not limited to any type of media dispensed from or otherwise provided by the reservoir, and the subject matter may be implemented with other medical devices or electronic devices other than fluid infusion devices. For example, any electronic device could be configured to analyze and identify the composition and concentration of a fluid contained in a conduit through transmission of a beam of energy and processing of the resulting signal through spectroscopic analysis.


For the sake of brevity, conventional techniques related to glucose sensing and/or monitoring, closed-loop glucose control, sensor calibration, electrical signals and related processing, electrical interconnects or interfaces, packaging, fluid communications, fluid monitoring or measuring, and other functional aspects of the subject matter may not be described in detail herein. In addition, certain terminology may also be used in the herein for the purpose of reference only, and thus is not intended to be limiting. For example, terms such as “first”, “second”, and other such numerical terms referring to structures do not imply a sequence or order unless clearly indicated by the context. The foregoing description may also refer to elements or nodes or features being “connected” or “coupled” together. As used herein, unless expressly stated otherwise, “coupled” means that one element/node/feature is directly or indirectly joined to (or directly or indirectly communicates with) another element/node/feature, and not necessarily mechanically.


While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. For example, the subject matter described herein is not necessarily limited to the infusion devices and related systems described herein. Moreover, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application. Accordingly, details of the exemplary embodiments or other limitations described above should not be read into the claims absent a clear intention to the contrary.

Claims
  • 1. A method for identifying a fluid for delivery to a body of a user, the method comprising: holding a first fluid in a reservoir;coupling the reservoir to a device housing having a conduit;coupling the device housing to an infusion device with a connector, wherein the connector comprises: a coupling directly connected to the reservoir to establish fluid communication from the reservoir to the conduit;a wall having an internal surface and an external surface, wherein the internal surface bounds the conduit;a transmitter element mounted on the connector;a receiver element mounted on the connector; andan identifier element mounted on the connector and coupled to the receiver element;directing flow of the first fluid through the conduit;transmitting an initial beam of energy from the transmitter element into contact with the first fluid;altering the initial beam of energy through interaction with the first fluid by absorbing, refracting and/or reflecting the beam of energy to create a first altered beam of energy, wherein the first altered beam of energy is different from the initial beam of energy;receiving the first altered beam of energy with the receiver element; andanalyzing the first altered beam to identify the first fluid with the identifier element.
  • 2. The method of claim 1 wherein analyzing the first altered beam to identify the fluid comprises comparing the first altered beam of energy with stored data associated with selected fluids to identify the first fluid.
  • 3. The method of claim 1 wherein transmitting the initial beam of energy comprises transmitting a beam of infrared light or near infrared light.
  • 4. The method of claim 1 further comprising: replacing the first fluid with a second fluid;directing flow of the second fluid through the conduit;transmitting the initial beam of energy from the transmitter element into contact with the second fluid;altering the initial beam of energy through interaction with the second fluid by absorbing, refracting and/or reflecting the beam of energy to create a second altered beam of energy, wherein the second altered beam of energy is different from the initial beam of energy and is different from the first altered beam of energy;receiving the second altered beam of energy with the receiver element; andanalyzing the second altered beam to identify the second fluid with the identifier element.
  • 5. The method of claim 4 wherein the initial beam of energy is not associated with the first fluid or with the second fluid.
  • 6. The method of claim 1 wherein the initial beam of energy is not associated with the first fluid.
  • 7. The method of claim 1 further comprising securing the device housing to skin of the user.
  • 8. The method of claim 7 further comprising: while the device housing is secured to the skin of the user, replacing the first fluid with a second fluid;directing flow of the second fluid through the conduit;transmitting the initial beam of energy from the transmitter element into contact with the second fluid;altering the initial beam of energy through interaction with the second fluid by absorbing, refracting and/or reflecting the beam of energy to create a second altered beam of energy, wherein the second altered beam of energy is different from the initial beam of energy and is different from the first altered beam of energy;receiving the second altered beam of energy with the receiver element; andanalyzing the second altered beam to identify the second fluid with the identifier element.
  • 9. The method of claim 7 wherein the reservoir is a first reservoir, and wherein the method further comprises: while the device housing is secured to the skin of the user, replacing the first reservoir with a second reservoir containing a second fluid;directing flow of the second fluid through the conduit;transmitting the initial beam of energy from the transmitter element into contact with the second fluid;altering the initial beam of energy through interaction with the second fluid by absorbing, refracting and/or reflecting the beam of energy to create a second altered beam of energy, wherein the second altered beam of energy is different from the initial beam of energy and is different from the first altered beam of energy;receiving the second altered beam of energy with the receiver element; andanalyzing the second altered beam to identify the second fluid with the identifier element.
US Referenced Citations (246)
Number Name Date Kind
3631847 Hobbs, II Jan 1972 A
4212738 Henne Jul 1980 A
4270532 Franetzki et al. Jun 1981 A
4282872 Franetzki et al. Aug 1981 A
4373527 Fischell Feb 1983 A
4395259 Prestele et al. Jul 1983 A
4433072 Pusineri et al. Feb 1984 A
4443218 Decant, Jr. et al. Apr 1984 A
4494950 Fischell Jan 1985 A
4542532 McQuilkin Sep 1985 A
4550731 Batina et al. Nov 1985 A
4559037 Franetzki et al. Dec 1985 A
4562751 Nason et al. Jan 1986 A
4671288 Gough Jun 1987 A
4678408 Nason et al. Jul 1987 A
4685903 Cable et al. Aug 1987 A
4731051 Fischell Mar 1988 A
4731726 Allen, III Mar 1988 A
4781798 Gough Nov 1988 A
4803625 Fu et al. Feb 1989 A
4809697 Causey, III et al. Mar 1989 A
4826810 Aoki May 1989 A
4871351 Feingold Oct 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
5003298 Havel Mar 1991 A
5011468 Lundquist et al. Apr 1991 A
5019974 Beckers May 1991 A
5050612 Matsumura Sep 1991 A
5078683 Sancoff et al. Jan 1992 A
5080653 Voss et al. Jan 1992 A
5097122 Colman et al. Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5101814 Palti Apr 1992 A
5108819 Heller et al. Apr 1992 A
5153827 Coutre et al. Oct 1992 A
5165407 Wilson et al. Nov 1992 A
5247434 Peterson et al. Sep 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5284140 Allen et al. Feb 1994 A
5299571 Mastrototaro Apr 1994 A
5307263 Brown Apr 1994 A
5317506 Coutre et al. May 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5338157 Blomquist Aug 1994 A
5339821 Fujimoto Aug 1994 A
5341291 Roizen et al. Aug 1994 A
5350411 Ryan et al. Sep 1994 A
5356786 Heller et al. Oct 1994 A
5357427 Langen et al. Oct 1994 A
5368562 Blomquist et al. Nov 1994 A
5370622 Livingston et al. Dec 1994 A
5371687 Holmes, II et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5403700 Heller et al. Apr 1995 A
5411647 Johnson et al. May 1995 A
5482473 Lord et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5505709 Funderburk et al. Apr 1996 A
5497772 Schulman et al. May 1996 A
5543326 Heller et al. Aug 1996 A
5569186 Lord et al. Oct 1996 A
5569187 Kaiser Oct 1996 A
5573506 Vasko Nov 1996 A
5582593 Hultman Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593390 Castellano et al. Jan 1997 A
5593852 Heller et al. Jan 1997 A
5594638 Illiff Jan 1997 A
5609060 Dent Mar 1997 A
5626144 Tacklind et al. May 1997 A
5630710 Tune et al. May 1997 A
5643212 Coutre et al. Jul 1997 A
5660163 Schulman et al. Aug 1997 A
5660176 Iliff Aug 1997 A
5665065 Colman et al. Sep 1997 A
5665222 Heller et al. Sep 1997 A
5685844 Marttila Nov 1997 A
5687734 Dempsey et al. Nov 1997 A
5704366 Tacklind et al. Jan 1998 A
5750926 Schulman et al. May 1998 A
5754111 Garcia May 1998 A
5764159 Neftel Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5779665 Mastrototaro et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5791344 Schulman et al. Aug 1998 A
5800420 Gross et al. Sep 1998 A
5807336 Russo et al. Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5832448 Brown Nov 1998 A
5840020 Heinonen et al. Nov 1998 A
5861018 Feierbach et al. Jan 1999 A
5868669 Iliff Feb 1999 A
5871465 Vasko Feb 1999 A
5879163 Brown et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5897493 Brown Apr 1999 A
5899855 Brown May 1999 A
5904708 Goedeke May 1999 A
5913310 Brown Jun 1999 A
5917346 Gord Jun 1999 A
5918603 Brown Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5940801 Brown Aug 1999 A
5956501 Brown Sep 1999 A
5960403 Brown Sep 1999 A
5965380 Heller et al. Oct 1999 A
5972199 Heller et al. Oct 1999 A
5978236 Faberman et al. Nov 1999 A
5997476 Brown Dec 1999 A
5999848 Gord et al. Dec 1999 A
5999849 Gord et al. Dec 1999 A
6009339 Bentsen et al. Dec 1999 A
6032119 Brown et al. Feb 2000 A
6043437 Schulman et al. Mar 2000 A
6081736 Colvin et al. Jun 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6101478 Brown Aug 2000 A
6103033 Say et al. Aug 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6134461 Say et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6162611 Heller et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6183412 Benkowski et al. Feb 2001 B1
6246992 Brown Jun 2001 B1
6259937 Schulman et al. Jul 2001 B1
6329161 Heller et al. Dec 2001 B1
6408330 DeLaHuerga Jun 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6472122 Schulman et al. Oct 2002 B1
6484045 Holker et al. Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6503381 Gotoh et al. Jan 2003 B1
6514718 Heller et al. Feb 2003 B2
6544173 West et al. Apr 2003 B2
6553263 Meadows et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560741 Gerety et al. May 2003 B1
6565509 Say et al. May 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6589229 Connelly et al. Jul 2003 B1
6591125 Buse et al. Jul 2003 B1
6592745 Feldman et al. Jul 2003 B1
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607658 Heller et al. Aug 2003 B1
6616819 Liamos et al. Sep 2003 B1
6618934 Feldman et al. Sep 2003 B1
6623501 Heller et al. Sep 2003 B2
6641533 Causey, III et al. Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6659980 Moberg et al. Dec 2003 B2
6671554 Gibson et al. Dec 2003 B2
6676816 Mao et al. Jan 2004 B2
6689265 Heller et al. Feb 2004 B2
6728576 Thompson et al. Apr 2004 B2
6733471 Ericson et al. May 2004 B1
6740072 Starkweather et al. May 2004 B2
6746582 Heller et al. Jun 2004 B2
6747556 Medema et al. Jun 2004 B2
6749740 Liamos et al. Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6809653 Mann et al. Oct 2004 B1
6817990 Yap et al. Nov 2004 B2
6827702 Lebel et al. Dec 2004 B2
6881551 Heller et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6893545 Gotoh et al. May 2005 B2
6895263 Shin et al. May 2005 B2
6916159 Rush et al. Jul 2005 B2
6932584 Gray et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6942518 Liamos et al. Sep 2005 B2
7153263 Carter et al. Dec 2006 B2
7153289 Vasko Dec 2006 B2
7323142 Pendo et al. Jan 2008 B2
7365847 Auton et al. Apr 2008 B2
7396330 Banet et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7621893 Moberg et al. Nov 2009 B2
8674288 Hanson et al. Mar 2014 B2
20010044731 Coffman et al. Nov 2001 A1
20020013518 West et al. Jan 2002 A1
20020022855 Bobroff et al. Feb 2002 A1
20020055857 Mault et al. May 2002 A1
20020082665 Haller et al. Jun 2002 A1
20020137997 Mastrototaro et al. Sep 2002 A1
20020161288 Shin et al. Oct 2002 A1
20030060765 Campbell et al. Mar 2003 A1
20030078560 Miller et al. Apr 2003 A1
20030088166 Say et al. May 2003 A1
20030144581 Conn et al. Jul 2003 A1
20030152823 Heller Aug 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030188427 Say et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030220552 Reghabi et al. Nov 2003 A1
20040061232 Shah et al. Apr 2004 A1
20040061234 Shah et al. Apr 2004 A1
20040064133 Miller et al. Apr 2004 A1
20040064156 Shah et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040074785 Holker et al. Apr 2004 A1
20040093167 Braig et al. May 2004 A1
20040097796 Berman et al. May 2004 A1
20040102683 Khanuja et al. May 2004 A1
20040111017 Say et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040167465 Mihai et al. Aug 2004 A1
20040193453 Butterfield Sep 2004 A1
20040263354 Mann et al. Dec 2004 A1
20050038331 Silaski et al. Feb 2005 A1
20050038680 McMahon et al. Feb 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20060229694 Schulman et al. Oct 2006 A1
20060238333 Welch et al. Oct 2006 A1
20060293571 Bao et al. Dec 2006 A1
20070088521 Shmueli et al. Apr 2007 A1
20070135866 Baker et al. Jun 2007 A1
20080154503 Wittenber et al. Jun 2008 A1
20090081951 Erdmann et al. Mar 2009 A1
20090082635 Baldus et al. Mar 2009 A1
20090131861 Braig May 2009 A1
20100121170 Rule May 2010 A1
20110009800 Dam Jan 2011 A1
20120232362 Gable Sep 2012 A1
20130204227 Bochenko Aug 2013 A1
20140128960 Greenslet et al. May 2014 A1
Foreign Referenced Citations (28)
Number Date Country
4329229 Mar 1995 DE
0319268 Nov 1988 EP
0806738 Nov 1997 EP
0880936 Dec 1998 EP
1338295 Aug 2003 EP
1631036 Mar 2006 EP
2218831 Nov 1989 GB
WO 9620745 Jul 1996 WO
WO 9636389 Nov 1996 WO
WO 9637246 Nov 1996 WO
WO 9721456 Jun 1997 WO
WO 9820439 May 1998 WO
WO 9824358 Jun 1998 WO
WO 9842407 Oct 1998 WO
WO 9849659 Nov 1998 WO
WO 9859487 Dec 1998 WO
WO 9908183 Feb 1999 WO
WO 9910801 Mar 1999 WO
WO 9918532 Apr 1999 WO
WO 9922236 May 1999 WO
WO 0010628 Mar 2000 WO
WO 0019887 Apr 2000 WO
WO 0048112 Aug 2000 WO
WO 02058537 Aug 2002 WO
WO 03001329 Jan 2003 WO
WO 03094090 Nov 2003 WO
WO 2005065538 Jul 2005 WO
WO-2017002023 Jan 2017 WO
Non-Patent Literature Citations (92)
Entry
PCT Search Report (PCT/US02/03299), dated Oct. 31, 2002, Medtronic Minimed, Inc.
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy.
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327.
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition.
Brackenridge B P (1992). Carbohydrate Gram Counting a Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28.
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc.
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138.
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283.
Kulkarni K et al. (1999). Carbohydrate Counting a Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc.
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142.
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38.
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company.
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed⋅Technologies.
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60.
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed⋅Technologies.
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78.
Disetronic My Choice™ D-TRON™ Insulin Pump Reference Manual. (Publication or release date no later than Nov. 2007).
Disetronic H-TRON® plus Quick Start Manual. (Publication or release date no later than Nov. 2007).
Disetronic My Choice H-TRONplus Insulin Pump Reference Manual. (Publication or release date no later than Nov. 2007).
Disetronic H-TRON®plus Reference Manual. (Publication or release date no later than Nov. 2007).
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506_pic.htm.
(MiniMed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm.
(MiniMed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq_pract.htm.
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm.
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide.
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines / MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages.
(MiniMed, 1996). MiniMed™ 507 Insulin Pump User's Guide.
(MiniMed, 1997). MiniMed™ 507 Insulin Pump User's Guide.
(MiniMed, 1998). MiniMed 507C Insulin Pump User's Guide.
(MiniMed International, 1998). MiniMed 507C Insulin Pump for those who appreciate the difference.
(MiniMed Inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy.
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life.
(MiniMed, 2000). MiniMed® 508 User's Guide.
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator.
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy.
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management.
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence.
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version.
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584.
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696.
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197.
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473.
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540.
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70.
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241.
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analylica Chimica Acta, 249, 1991, pp. 43-54.
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357.
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, 62, pp. 258-263. (Publication or release date no later than Nov. 2007).
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975.
Hashiguchi, Yasuhiro, MD. et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389.
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134.
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179.
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714.
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468.
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Linearity,” Sensors and Actuators, B. 10, 1992, pp. 37-40.
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765.
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52.
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36.
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165.
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144.
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991.
Mckean, Brian. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532.
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16.
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484.
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Navel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077.
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172.
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358.
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine-co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103.
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663.
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220.
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406.
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only for a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9.
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292.
Shichiri, Motoaki, el al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202.
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313.
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275.
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301.
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131.
Shichiri, Motoaki, et al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370.
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041.
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942.
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40.
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators. vol. 18, 1989, pp. 297-307.
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091.
Urban, G., et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739.
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562.
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233.
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847.
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98.
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytica Chimica Acta, vol. 218, 1989, pp. 137-142.
Related Publications (1)
Number Date Country
20180236169 A1 Aug 2018 US